STAMBP-IN-1 is a small-molecule inhibitor of STAMBP deubiquitinase, and interrupts STAMBP-Ub-NALP7 interaction. STAMBP-IN-1 decreases protein level of its inflammasome substrate NALP7 and suppresses IL-1b release after Toll-like receptor (TLR) agonism. STAMBP-IN-1 inhibits the activity of STAMBP to cleave recombinant di-Ub with an IC50 value of 0.33 mM

[Cys3, 6, Tyr8, Pro10]-Substance P

4,6-Benzilidine-D-Glucose is a clinical antitumor compound showing antitumor activity in rats with chemically induced hepatocellular carcinoma.